At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co. Ltd. presented details on a new SERCA inhibitor – SYN-4569 – as a potential approach to treat multiple system atrophy-cerebellar type (MSA-C).